[go: up one dir, main page]

WO2001087305A3 - Method for treating functional dyspepsia using alosetron - Google Patents

Method for treating functional dyspepsia using alosetron Download PDF

Info

Publication number
WO2001087305A3
WO2001087305A3 PCT/US2001/015633 US0115633W WO0187305A3 WO 2001087305 A3 WO2001087305 A3 WO 2001087305A3 US 0115633 W US0115633 W US 0115633W WO 0187305 A3 WO0187305 A3 WO 0187305A3
Authority
WO
WIPO (PCT)
Prior art keywords
alosetron
functional dyspepsia
treating functional
treating
dyspepsia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/015633
Other languages
French (fr)
Other versions
WO2001087305A2 (en
Inventor
Allen Wayne Mangel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to EP01935516A priority Critical patent/EP1284732A2/en
Priority to AU2001261606A priority patent/AU2001261606A1/en
Priority to JP2001583773A priority patent/JP2003533482A/en
Publication of WO2001087305A2 publication Critical patent/WO2001087305A2/en
Publication of WO2001087305A3 publication Critical patent/WO2001087305A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This invention relates to the use of alosetron in the treatment of functional dyspepsia.
PCT/US2001/015633 2000-05-18 2001-05-15 Method for treating functional dyspepsia using alosetron Ceased WO2001087305A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01935516A EP1284732A2 (en) 2000-05-18 2001-05-15 Method for treating functional dyspepsia using alosetron
AU2001261606A AU2001261606A1 (en) 2000-05-18 2001-05-15 Method for treating functional dyspepsia
JP2001583773A JP2003533482A (en) 2000-05-18 2001-05-15 How to treat functional dyspepsia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20530800P 2000-05-18 2000-05-18
US60/205,308 2000-05-18

Publications (2)

Publication Number Publication Date
WO2001087305A2 WO2001087305A2 (en) 2001-11-22
WO2001087305A3 true WO2001087305A3 (en) 2002-04-25

Family

ID=22761668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/015633 Ceased WO2001087305A2 (en) 2000-05-18 2001-05-15 Method for treating functional dyspepsia using alosetron

Country Status (4)

Country Link
EP (1) EP1284732A2 (en)
JP (1) JP2003533482A (en)
AU (1) AU2001261606A1 (en)
WO (1) WO2001087305A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100091A1 (en) * 2002-05-24 2003-12-04 Epidauros Biotechnologie Ag Means and methods for improved treatment using 'setrones'
EP1727527A1 (en) * 2004-03-19 2006-12-06 Solvay Pharmaceuticals GmbH Use of a 5-ht3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain
US7820690B2 (en) 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0485962A2 (en) * 1990-11-16 1992-05-20 Syntex (U.S.A.) Inc. New tricyclic compounds
EP0490263A1 (en) * 1990-12-07 1992-06-17 Syntex (U.S.A.) Inc. Alpha-oxoacetamide derivatives
US5202333A (en) * 1989-11-28 1993-04-13 Syntex (U.S.A.) Inc. Tricyclic 5-HT3 receptor antagonists
US5516782A (en) * 1991-03-07 1996-05-14 G. D. Searle & Co. New meso-azacyclic aromatic acid amides and esters as novel serotonergic agents
WO1999017755A2 (en) * 1997-10-07 1999-04-15 Glaxo Group Limited Medicaments
WO2001041748A2 (en) * 1999-12-10 2001-06-14 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
WO2001045685A2 (en) * 1999-12-20 2001-06-28 Glaxo Group Limited Formulations of adenosine a1 agonists

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202333A (en) * 1989-11-28 1993-04-13 Syntex (U.S.A.) Inc. Tricyclic 5-HT3 receptor antagonists
EP0485962A2 (en) * 1990-11-16 1992-05-20 Syntex (U.S.A.) Inc. New tricyclic compounds
EP0490263A1 (en) * 1990-12-07 1992-06-17 Syntex (U.S.A.) Inc. Alpha-oxoacetamide derivatives
US5516782A (en) * 1991-03-07 1996-05-14 G. D. Searle & Co. New meso-azacyclic aromatic acid amides and esters as novel serotonergic agents
WO1999017755A2 (en) * 1997-10-07 1999-04-15 Glaxo Group Limited Medicaments
WO2001041748A2 (en) * 1999-12-10 2001-06-14 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
WO2001045685A2 (en) * 1999-12-20 2001-06-28 Glaxo Group Limited Formulations of adenosine a1 agonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COULIE B. ET AL: "New therapies for functional bowel disease.", CURRENT GASTROENTEROLOGY REPORTS, vol. 2, 2000, pages 355 - 363, XP001041929 *
GUPTA Y.K. ET AL.: "Therapeutic potentials of 5-HT receptor modulators", INDIAN JOURNAL OF PHARMACOLOGY, vol. 26, 1994, pages 94 - 107, XP001041938 *
MAXTON D.G. ET AL.: "Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?", ALIMENT. PHARMACOL. THER., vol. 10, 1996, pages 595 - 599, XP001041947 *

Also Published As

Publication number Publication date
EP1284732A2 (en) 2003-02-26
WO2001087305A2 (en) 2001-11-22
AU2001261606A1 (en) 2001-11-26
JP2003533482A (en) 2003-11-11

Similar Documents

Publication Publication Date Title
WO2001060347A3 (en) Method for treating ocular pain
AU2002325835A1 (en) Treatment method, which promotes the removal of dirt, for the surfaces of textiles and non-textiles
PL364995A1 (en) Method for the treatment or prevention of flavivirus
HUP0302739A3 (en) Method for the treatment of tobacco
AU2001285747A1 (en) Method for the treatment of tobacco
AU2003247624A8 (en) Method of treating the syndrome of lipodystrophy
AU2002225930A1 (en) Methods for treating phosphatide-containing mixtures
MXPA03001717A (en) Method for treatment of migraine.
EP1465968A4 (en) Methods for treating deodorizer distillate
AU2001286983A1 (en) Method of treatment
MXPA02012907A (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity.
AU2001273609A1 (en) Process for treating wood
MXPA03006607A (en) Combined method for treating hormono-dependent disorders.
PL368948A1 (en) Process and composition for treating wood
MXPA03003347A (en) Method of purifying plavastatin.
EP1667827A4 (en) Process for the treatment of wood
AU2001244834A1 (en) Novel strain for decomposing tmah, and method of wastewater treatment using the same
MXPA03004017A (en) Method for the treatment of inflammation.
WO2001087305A3 (en) Method for treating functional dyspepsia using alosetron
AU2002236116A1 (en) Method to treat soapy wastewater
GB0123898D0 (en) Method for treating objects
ZA200101058B (en) Process for the treatment of gases.
GB0008921D0 (en) Method of treatment
GB0026838D0 (en) Treatment method
AU2001235776A1 (en) Apparatus and method for water treatment by adsorption

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10276238

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001935516

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001935516

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001935516

Country of ref document: EP